09 January 2019 | News
“As a drug development company, BCMA is the first of multiple assets that CBMG is advancing amongst our oncology pipeline beyond our collaboration with a global leader in cell therapy”
Cellular Biomedicine Group Inc., a biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, has announced the initiation of patient recruitment to support the study of anti-BCMA CAR-T therapy targeting relapsed and refractory Multiple Myeloma in China.
"China has seen a substantial increase in the incidence of Multiple Myeloma. As a drug development company, BCMA is the first of multiple assets that CBMG is advancing amongst our oncology pipeline beyond our collaboration with a global leader in cell therapy," commented Tony (Bizuo) Liu, Chief Executive Officer of the Company.
"We plan to provide updates in the near future on the progress of our other proprietary technologies, including anti-CD22 and anti-CD20 CAR-T targeting relapsed Acute Lymphoblastic Leukemia (ALL) and Diffuse Large B-cell Lymphoma (DLBCL) patients post anti-CD19 CAR-T treatment, Alpha Fetoprotein T-cell Receptor (AFP-TCR-T) for Hepatocellular Carcinoma, and next generation Tumor Infiltrating Lymphocytes (TIL) for the treatment of non-small cell lung cancer (NSCLC) and other solid tumor indications. We hope to be able to provide expeditious, safe and effective therapies to cancer patients who currently have limited treatment options," He stated further.